gainbot
BriefMoversScreensSectorsEarningsIPOsNewsDividends & splitsScreenerWatchlistLearn
NASDAQ · MGTXHealthcareBiotechnology

MeiraGTx Holdings plc Ordinary Shares (MGTX)

$9.42−1.05%
Close Nov 4, 2026 · split-adjusted
Nov 2, 2026$9.32▲ 6.76% in range
Nov 3, 2025Low $6.99 · High $14.97Nov 2, 2026
What changed · written from our data
As of Nov 4, 2026

MeiraGTx Holdings plc closed at $9.42 on Nov 4, down 1.05%, 37.1% below its 52-week closing high. Volume of 597.9K shares was 0.79× its 20-day average (below normal).

Split-adjusted performance: -11.1% over one month, -4.8% over six months, +7.9% over one year.

In the quarter ended Jun 30, 2026, revenue was $321.43M, up 8608.6% from a year earlier, with a net margin of 50.0%.

Short interest was 6.4M shares at the Oct 15 settlement, up 7.4% from the prior report (10.8% of float, 6.5 days to cover).

Market cap$904.7M96.0M shares
Revenue · quarter$321.4M+8608.6% YoY
Diluted EPS$1.71—
P/E · TTM11.5×P/S 2.3×
Net margin50.0%Gross 97.8%
Dividend yieldNone
52-week range6.99 – 14.97−37.1% from high
Volume597.9K0.79× 20-day avg
Volatility · 60d47.5%Annualised
Short % of float10.8%6.5 days to cover
Net cash$21.8MCash $143.2M
Next earnings—Not scheduled
Split-adjusted performance
1W −3.4%1M −11.1%3M −26.3%6M −4.8%YTD +18.5%1Y +7.9%3Y +111.7%5Y −56.1%

Earnings reactions

History →

No reported quarters with price history yet.

Rank within Biotechnology

Percentile among 139 companies (100 = best)

6-month momentum64
Revenue growth97
Net margin96
Value (low P/E)69
Size71

Industry medians: 6-month return −19.2%, revenue growth +8.8%, net margin −312.9%, P/E 22.0×.

Short interest

Details →
Shares short6.4M+7.4% vs prior
Days to cover6.5Settled Oct 15
% of float10.8%
Short vol. 10d63.3%of daily volume

Closest peers by size in Biotechnology

CompanyPriceToday6MRev. growthNet marginP/EMkt cap
MGTXMeiraGTx Holdings$9.42−1.05%−4.8%+8608.6%50.0%11.5$904.7M
PRMEPrime Medicine$4.97+9.23%+45.7%+3.5%−3649.0%—$901.4MCompare
GLUEMonte Rosa Therapeutics$10.82+3.94%−46.9%−61.3%−483.9%—$923.1MCompare
ODTXOdyssey Therapeutics$19.50−9.60%————$937.1MCompare
CGEMCullinan Therapeutics$12.49−20.70%−16.7%———$803.8MCompare
DNAGinkgo Bioworks Holdings$11.65+8.27%+15.6%−48.5%−231.7%—$784.5MCompare
SANASana Biotechnology$2.56+4.92%−29.7%———$766.4MCompare
ATTOAttovia Therapeutics$15.60+2.16%————$712.2MCompare
SLDBSolid Biosciences$6.52+3.82%−9.4%———$699.1MCompare

News about MeiraGTx Holdings

All news →
What This MeiraGTx Insider Sale Might Mean With Two Drug Filings NearThe Motley Fool · Jul 12, 2026▲ PositiveEli Lilly Partner MeiraGTx Regains Rights For Genetic Eye Disease Drug From Johnson & JohnsonBenzinga · Apr 16, 2026▼ NegativeMeiraGTx Announces the Acquisition of Botaretigene Sparoparvovec (bota-vec) for the Treatment of X-linked Retinitis Pigmentosa (XLRP)Benzinga · Apr 16, 2026▲ Positive

Quick answers

What does MeiraGTx Holdings plc do?
MeiraGTx Holdings PLC is a vertically integrated, clinical-stage genetic medicines company focused on developing targeted therapies for diseases with high unmet need, including radiation-induced xerostomia, Parkinson's disease, and AIPL1-associated retinal dystrophy. The company's pipeline is supported by end-to-end in-house manufacturing capabilities, including GMP viral vector production, plasmid manufacturing, and quality control, enabling development from IND to commercial supply.
What is MGTX's market cap?
$904.73M, based on the Nov 4 close of $9.42.
What is MGTX's P/E ratio?
11.5× trailing-twelve-month earnings of $78.98M.
Does MeiraGTx Holdings plc pay a dividend?
No regular cash dividend has been paid in the last year.
How much of MGTX is sold short?
6.4M shares, 10.8% of float, as of Oct 15, 2026.
What sector is MGTX in?
Healthcare, in the Biotechnology industry.

About MeiraGTx Holdings

MeiraGTx Holdings PLC is a vertically integrated, clinical-stage genetic medicines company focused on developing targeted therapies for diseases with high unmet need, including radiation-induced xerostomia, Parkinson's disease, and AIPL1-associated retinal dystrophy. The company's pipeline is supported by end-to-end in-house manufacturing capabilities, including GMP viral vector production, plasmid manufacturing, and quality control, enabling development from IND to commercial supply. It also utilizes proprietary platforms in viral vector optimization and riboswitch-based gene regulation to enhance efficacy and reduce dosage. The company operates in the United States, the United Kingdom, and the European Union.

HQ: New York, NY393 employeesListed Jun 8, 2018meiragtx.com

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology